Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Equasens S.A. (EQS.PA)
Villers-lès-Nancy, GE, FR
Equasens S.A., established in 1996 and headquartered in Villers-les-Nancy, France, delivers a diverse portfolio of information technology solutions tailored for the European healthcare industry. The company primarily equips pharmacies and their networks with advanced management systems, including LGPI global services and OffiCentral. Pharmacists leverage a comprehensive suite of tools designed to streamline daily business operations, such as OffiMSS, OffiSecure, OffiProtect, OffiPass, OffiSeen, OffiCash, Offizzy, and OffiLocker. To foster stronger customer relationships and engagement, Equasens provides innovative solutions like OffiTag, OffiTouch, OffiMédia, OffiConnect, alongside automation systems and loyalty program management. Beyond operational software, the company offers analytical insights through its My Pilot tool and professional development opportunities via OffiLearning, an e-learning platform. A key area of focus is patient support, with offerings spanning compliance monitoring software, Multimeds, Automeds, OffiTéléconsult, and essential pharmaceutical and shared medical record services. The company's specialized systems include ULTIMATE, which combines efficient pharmacy administration with enhanced patient care, and FARMACLICK, a protocol facilitating communication between pharmacies and wholesale distributors (the latter also served by DIFARM). Additional retail management tools comprise PHARE and the SOPHIA pharmacy application, complemented by OffiMédia POS displays. Equasens also addresses specific health needs, such as chronic renal failure management with eNephro, and simplifies the administration of patient education programs through TPE Pilot. Further extending its reach across the healthcare sector, Equasens offers various dedicated solutions like NOVIACARE, CARELIB (for home and nursing home care), KAPELSE, TITAN, ANTHADINE software, the MOBISOINS mobile tool, MICROSOINS for in-home nursing care, and LOGICLIC. For holistic patient journey oversight, the AXIGATE solutions and CHORUS platform are available. Supplementary services include medical telesecretarial assistance for healthcare professionals and equipment lease financing options. Equasens S.A. functions as a subsidiary of Marque Verte Sante.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.21% | +3.55% | +4.93% | +11.32% | -8.38% | -12.56% | -20.51% | -48.02% | -56.66% | +60.94% | +850.48% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 3 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Software - Application: +13.0%+9.1% Q4'25: +12.5% (vs Q4'23)
-
EPS growth Software - Application: +28.6%+8.4% Q4'25: -13.3% (vs Q4'23)
-
FCF margin FCF growth · Software - Application: +45.3%+21.0% Q4'25: +15.9% (vs Q4'23)
-
EBIT margin Software - Application: +9.4%+22.2% ★ Q4'25: -45.5% (vs Q4'23)
-
ROIC Software - Application: +7.5%+18.1% ★ Q4'25: -75.5% (vs Q4'23)
-
Share dilution Software - Application: +0.0%+0.0% Q4'25: +0.8% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Software - Application: -1.16×0.76× Q4'25: -0.30× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 3 Rev. Ana. 3 EPS Ana. |
Dec 2027 4 Rev. Ana. 3 EPS Ana. |
Dec 2028 2 Rev. Ana. 2 EPS Ana. |
Dec 2029 1 Rev. Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
113.48M
est: 113.50M (0.0%)
|
128.38M
est: 128.39M (0.0%)
|
129.67M
est: 146.80M (-11.7%)
|
148.48M
est: 148.50M (0.0%)
|
158.57M
est: 158.55M (+0.0%)
|
171.75M
est: 171.80M (0.0%)
|
193.07M
est: 193.07M (+0.0%)
|
214.08M
est: 214.10M (0.0%)
|
219.79M
est: 215.16M (+2.2%)
|
216.80M
est: 216.60M (+0.1%)
|
236.50M
est: 236.30M (+0.1%)
|
259.90M
258.87M – 260.67M
+10.0% YoY
|
276.15M
273.80M – 278.50M
+6.3% YoY
|
292.05M
290.21M – 293.75M
+5.8% YoY
|
307.90M
305.96M – 309.69M
+5.4% YoY
|
| EBITDA |
31.17M
est: 35.94M (-13.3%)
|
34.85M
est: 40.65M (-14.3%)
|
39.55M
est: 46.48M (-14.9%)
|
44.22M
est: 47.02M (-6.0%)
|
48.41M
est: 50.20M (-3.6%)
|
55.53M
est: 54.40M (+2.1%)
|
63.77M
est: 61.13M (+4.3%)
|
67.36M
est: 67.79M (-0.6%)
|
71.30M
est: 67.13M (+6.2%)
|
62.99M
est: 67.58M (-6.8%)
|
70.96M
est: 73.72M (-3.7%)
|
81.09M
80.76M – 81.33M
+10.0% YoY
|
86.16M
85.42M – 86.89M
+6.3% YoY
|
91.12M
90.54M – 91.65M
+5.8% YoY
|
96.06M
95.45M – 96.62M
+5.4% YoY
|
| EBIT |
29.46M
est: 29.16M (+1.0%)
|
31.39M
est: 32.98M (-4.8%)
|
34.26M
est: 37.71M (-9.2%)
|
38.99M
est: 38.15M (+2.2%)
|
40.96M
est: 40.73M (+0.6%)
|
46.52M
est: 44.14M (+5.4%)
|
52.44M
est: 49.60M (+5.7%)
|
55.07M
est: 55.00M (+0.1%)
|
58.08M
est: 53.16M (+9.2%)
|
44.64M
est: 53.52M (-16.6%)
|
52.44M
est: 58.39M (-10.2%)
|
64.22M
63.96M – 64.41M
+10.0% YoY
|
68.23M
67.65M – 68.82M
+6.3% YoY
|
72.16M
71.71M – 72.58M
+5.8% YoY
|
76.08M
75.60M – 76.52M
+5.4% YoY
|
| Net Income |
18.79M
est: 19.42M (-3.2%)
|
20.57M
est: 21.09M (-2.5%)
|
23.14M
est: 22.76M (+1.6%)
|
25.43M
est: 26.08M (-2.5%)
|
28.40M
est: 29.51M (-3.8%)
|
30.71M
est: 32.32M (-5.0%)
|
39.12M
est: 36.88M (+6.1%)
|
46.38M
est: 45.98M (+0.9%)
|
47.05M
est: 42.25M (+11.3%)
|
36.20M
est: 38.45M (-5.8%)
|
39.30M
est: 37.10M (+5.9%)
|
44.50M
43.58M – 46.91M
+19.9% YoY
|
51.13M
48.13M – 51.95M
+14.9% YoY
|
54.93M
54.78M – 55.08M
+7.4% YoY
|
—
— – —
-100.0% YoY
|
| SGA |
—
est: 122.2K (-100.0%)
|
—
est: 138.2K (-100.0%)
|
-648.0K
est: 158.1K (-510.0%)
|
—
est: 159.9K (-100.0%)
|
8.0K
est: 170.7K (-95.3%)
|
—
est: 185.0K (-100.0%)
|
—
est: 207.9K (-100.0%)
|
71.0K
est: 230.5K (-69.2%)
|
427.0K
est: 231.6K (+84.3%)
|
674.0K
est: 233.2K (+189.0%)
|
—
est: 254.4K (-100.0%)
|
279.8K
278.7K – 280.6K
+10.0% YoY
|
297.3K
294.8K – 299.9K
+6.3% YoY
|
314.4K
312.5K – 316.3K
+5.8% YoY
|
331.5K
329.4K – 333.4K
+5.4% YoY
|
| EPS |
1.25
est: 1.28 (-2.3%)
|
1.37
est: 1.39 (-1.5%)
|
1.55
est: 1.50 (+3.3%)
|
1.70
est: 1.72 (-1.1%)
|
1.89
est: 1.95 (-2.8%)
|
2.04
est: 2.13 (-4.2%)
|
2.60
est: 2.43 (+7.0%)
|
3.08
est: 3.03 (+1.7%)
|
3.13
est: 2.81 (+11.5%)
|
2.41
est: 2.53 (-4.9%)
|
2.59
est: 2.53 (+2.6%)
|
3.02
2.87 – 3.09
+19.4% YoY
|
3.33
3.17 – 3.42
+10.4% YoY
|
3.62
3.61 – 3.63
+8.7% YoY
|
—
— – —
-100.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-28 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-27 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-26 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-25 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-22 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-21 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-20 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-19 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-18 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-15 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-14 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-13 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-12 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-11 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-08 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-07 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-06 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-05 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-04 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-30 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-29 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-28 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-27 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-24 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-23 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-22 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-21 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-20 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-17 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-16 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Amundi MSCI EMU Small Cap ESG Broad Transition UCITS ETF Dist MMS.PA | 0.05% | 321.1K | 0.40% |
| 2 | iShares MSCI EMU Small Cap UCITS ETF CES1.L | 0.03% | 338.8K | 0.58% |
| 3 | UBS MSCI EMU Small Cap UCITS ETF EUR dis UEFD.DE | 0.03% | 224.6K | 0.33% |
| 4 | Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF Acc CEM.PA | 0.01% | 50.7K | 0.23% |
| 5 | Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF Dist X026.DE | 0.01% | 50.7K | 0.23% |
| 6 | Xtrackers MSCI Europe Small Cap UCITS ETF 1C XXSC.L | 0.01% | 451.2K | 0.30% |
| 7 | iShares MSCI Europe Small-Cap ETF IEUS | 0.01% | 21.1K | 0.41% |
| 8 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.01% | 865.8K | 0.06% |
| 9 | State Street SPDR MSCI Europe Small Cap Value Weighted UCITS ETF EUR Acc ZPRX.DE | 0.01% | 43.5K | 0.30% |
| 10 | iShares Currency Hedged MSCI EAFE Small-Cap ETF HSCZ | 0.01% | 12.4K | 0.83% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Denis Supplisson | Chief Executive Officer & Director | 315.9K | male |
| Grégoire De Rotalier | Deputy Chief Executive Officer, Deputy MD, Director of Healthcare, Medical & Social Software Division and Director | 306.3K | male |
| Dominique Pautrat | Director | 212.9K | male |
| Thierry Chapusot | Founder & Chairman of the Board | 24.0K | male |
| Frederique Schmidt | Group Chief Administrative & Financial Officer | — | female |
| Dominique Goursaud | Head of the Medical Solutions Division | — | male |
| Noelle Stoulig | Head of Communications | — | female |
| Sabrina Gharbi | Chief Human Resources Officer | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for EQS.PA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
